Stockscreener 앱 받기
0.40
1.48%
-0.006
시간 외 거래:
.38
-0.02
-5.00%
전일 마감가:
$0.406
열려 있는:
$0.3872
하루 거래량:
1.99M
Relative Volume:
0.07
시가총액:
$10.78M
수익:
$94,000
순이익/손실:
$-13.28M
주가수익비율:
-0.0548
EPS:
-7.2965
순현금흐름:
$-11.67M
1주 성능:
-8.59%
1개월 성능:
+58.10%
6개월 성능:
-70.12%
1년 성능:
-96.06%
1일 변동 폭
$0.38
$0.40
1주일 범위
$0.3669
$0.4618
52주 변동 폭
$0.21
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
명칭
AIM ImmunoTech Inc
전화
352 448 7797
주소
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.40 | 10.46M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
AIM ImmunoTech (AIM) seeks approvals to issue >19.99% shares, reverse split option - Stock Titan
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - The Manila Times
AIM Regains NYSE American Compliance After Equity-Boosting Financings - TradingView
AIM ImmunoTech (NYSE: AIM) lifts equity, regains NYSE American listing standards - Stock Titan
NYSE lifts compliance tag on AIM ImmunoTech after new equity financings - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
AIM ImmunoTech Announces $2.65 Million At-Market Financing to Advance Clinical Trials and Drug Development 1 - Minichart
AIM stock soars 42% as pancreatic cancer trial hits key enrollment milestone before schedule — CEO sees 'significant value-inflection period' ahead - MSN
AIM ImmunoTech Prices $1.3 Million Registered Direct Offering; Adds $5.3 Million Warrant Upside - TradingView
AIM ImmunoTech (NYSE: AIM) prices $2.65M stock and warrant financing deal - Stock Titan
$AIM ImmunoTech (AIM.US)$ - Moomoo
AIM ImmunoTech (AIM) shifts to majority-of-votes-cast rule for proposals - Stock Titan
[424B5] AIM ImmunoTech Inc. Prospectus Supplement (Debt Securities) - Stock Titan
AIM ImmunoTech announces $2.65M financing priced at market - MSN
symbol__ Stock Quote Price and Forecast - CNN
AIM News | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech raises $2.65M in direct offering - Investing.com UK
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules - TradingView
AIM ImmunoTech raises $2.65M in direct offering By Investing.com - Investing.com Nigeria
AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement - marketscreener.com
AIM ImmunoTech Inc. Announces $2.65 Million Registered Direct Offering and Private Placement - Quiver Quantitative
AIM ImmunoTech Announces $2.65M Financing Priced At-Market Under NYSE Amer Rules - Moomoo
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules - GlobeNewswire
AIM ImmunoTech files prospectus for resale of 31.3 million shares - scanx.trade
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead - Stocktwits
AIM ImmunoTech (AIM) resale filing covers 31.3M shares and major dilution risk - Stock Titan
been making money off these waves yo in out in out $AIM ImmunoTech (AIM.US)$ - Moomoo
Pancreatic cancer trial sees 22.3‑month survival gain in select patients - Stock Titan
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ - GlobeNewswire
AIM ImmunoTech Highlights Ampligen’s Emerging Ebola Treatment Potential - TipRanks
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness - The Manila Times
AIM ImmunoTech Releases Video Discussing Ampligen's Potential in Addressing Ebola Outbreak Concerns and Unmet Therapeutic Needs - Quiver Quantitative
AIM ImmunoTech (AIM) showcases Ampligen’s Ebola preclinical data and preparedness focus - Stock Titan
Lethal Ebola strain, no vaccines: AIM video explores Ampligen's potential - Stock Titan
avg was .27 but I doubled and triple down at .70 went balls deep! trust your knowledge not your emotions!💯 - Moomoo
$AIM ImmunoTech (AIM.US)$ 🤷♂️ when market turns around we be all in. f it - Moomoo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
$AIM ImmunoTech (AIM.US)$ on my dog ish!!! 🤑🤑 - Moomoo
$AIM ImmunoTech (AIM.US)$ will be back later for pullback :) - Moomoo
$AIM ImmunoTech (AIM.US)$ 🔥 💎 ✋️ - Moomoo
AIM ImmunoTech Inc (AIM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):